Add to the list of reasons not to have open heart surgery the potential use of Bayer’s (BAY) Trasylol to control bleeding. According to The Wall Street Journal "two studies published in 2006 suggested the drug doubled the risk of kidney failure/" The FDA is reviewing the drug due to the kidney issue and because" two additional studies have suggested the drug also could increase the risk of death."
The FDA has a "black box" warning on the Trasylol label. but the studies do raise that question of why the drug is on the market at all.
Maybe someone should look into this.
Douglas A. McIntyre